文献速递真菌感染

伊曲康唑与伏立康唑治疗初治慢性肺曲霉病的随机对照试验

Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.
PubMed 文献 · Lancet Infect Dis · 2025-10-29

在印度单中心开放标签优势试验中,116例初治慢性肺曲霉病患者随机接受伊曲康唑或伏立康唑治疗6个月,两组有利反应比例相似(69% vs 67%),但伏立康唑治疗相关不良事件显著更多(55% vs 34%)。伏立康唑不优于伊曲康唑,支持继续将伊曲康唑作为首选治疗。

要点

  • 伏立康唑6个月有利反应率69%,伊曲康唑67%,差异无统计学意义。
  • 伏立康唑治疗相关不良事件发生率55%,显著高于伊曲康唑的34%。
  • 伏立康唑组出现4例死亡,均与治疗无直接因果关系。

核心结论

  • 伏立康唑治疗慢性肺曲霉病不优于伊曲康唑,且不良事件发生率显著更高。
  • 研究支持继续将伊曲康唑作为慢性肺曲霉病的首选治疗,伏立康唑仍是合理替代。

研究设计与样本

  • 单中心、前瞻性、开放标签、优势性随机对照试验,在印度昌迪加尔一家三级医院胸科门诊开展。
  • 纳入116例初治成人慢性空洞性肺曲霉病或慢性纤维化性肺曲霉病患者,1:1随机接受口服伊曲康唑或伏立康唑200mg每日两次,治疗6个月。
  • 主要终点为改良意向治疗人群中6个月时达到有利反应(临床和影像学稳定或改善)的比例。

主要发现

  • 伏立康唑组发生4例死亡,均非直接归因于治疗。

临床怎么用

  • 伊曲康唑可作为慢性肺曲霉病的首选治疗。
  • 伏立康唑可作为合理替代,选择时应综合考虑患者耐受性、药物可及性和费用。

局限性

  • 单中心研究,结果外推需谨慎。
  • 开放标签设计,除影像评估外未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both itraconazole and voriconazole are used to treat chronic pulmonary aspergillosis. However, treatment success with itraconazole is only around 65-70%. Voriconazole, with its lower minimum inhibitory concentrations and better oral bioavailability, might offer improved outcomes, but no head-to-head comparison has been conducted to date. We aimed to evaluate whether oral voriconazole is superior to itraconazole in treating chronic pulmonary aspergillosis. METHODS: This single-centre, prospective, open-label, superiority trial was conducted at the chest clinic of a tertiary care hospital in Chandigarh, India. We enrolled treatment-naive adults aged 18 years or older with chronic cavitary pulmonary aspergillosis or chronic fibrosing pulmonary aspergillosis. We excluded those who denied consent, received any antifungal azoles for more than 3 weeks in the previous 6 months, or had other forms of aspergillosis. Participants were randomly assigned 1:1 to receive 200 mg twice daily of oral itraconazole or oral voriconazole for 6 months, using a computer-generated randomisation sequence with variable block sizes (4-8). Participants, staff administering the interventions, clinical outcome assessors, and data analysts were not masked to treatment assignment; a radiologist masked to clinical details and treatment allocation evaluated chest images. The primary outcome was the proportion of participants achieving a favourable response (clinical and radiological stability or improvement) at 6 months in the modified intention-to-treat population, which included all participants who received at least one dose of the allocated treatment. The safety analyses (a secondary outcome) were also performed in the modified intention-to-treat population. This trial is registered at ClinicalTrials.gov (NCT04824417) and is complete. FINDINGS: Between April 15, 2021, and May 31, 2024, 150 individuals were screened, and 116 were randomly assigned to receive itraconazole (n=58) or voriconazole (n=58). Of the 116 participants, 74 (64%) were men, 42 (36%) were women, and the mean age was 45·9 years (SD 14·4). All participants received at least one dose of the study drug and were included in the primary analysis. The proportion of participants achieving a favourable response at 6 months was similar in both groups (69% [40 of 58] receiving voriconazole vs 67% [39 of 58] receiving itraconazole; absolute risk reduction -0·02 [95% CI -0·2 to 0·15], p=0·84). Voriconazole was associated with significantly more treatment-related adverse events than itraconazole (55% [32 of 58] of participants receiving voriconazole vs 34% [20 of 58] receiving itraconazole, p=0·025). There were four deaths, all in the voriconazole group; none were directly attributable to the treatment. INTERPRETATION: Voriconazole was not superior to itraconazole for treating chronic pulmonary aspergillosis and was associated with a significantly higher incidence of adverse events. Our findings support the continued use of itraconazole as the preferred therapy for chronic pulmonary aspergillosis, although voriconazole remains a reasonable alternative. The choice between the two agents should be guided by factors such as patient tolerance, drug availability, and cost considerations. FUNDING: Cipla Pharmaceuticals, India.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sehgal IS, Agarwal R, Dhooria S, et al. Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2025. PMID: 41175884. doi:10.1016/S1473-3099(25)00537-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。